Onyx Pharmaceuticals (ONXX) +4.1% premarket after announcing FDA acceptance of its new drug application for carfilzomib, a next generation proteasome inhibitor for the potential treatment of patients with relapsed and refractory multiple myeloma.
For the latest updates on the stock market, visit,
http://daytradingstock-blog.blogspot.com/